Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Pfizer Inc (PFE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 211,962,848
  • Shares Outstanding, K 5,960,710
  • Annual Sales, $ 52,824 M
  • Annual Income, $ 7,215 M
  • 36-Month Beta 1.01
  • Price/Sales 3.99
  • Price/Cash Flow 10.46
  • Price/Book 3.44

Price Performance

See More
Period Period Low Period High Performance
1-Month
34.10 +3.56%
on 10/31/17
36.78 -3.97%
on 10/23/17
-0.88 (-2.43%)
since 10/17/17
3-Month
32.32 +9.28%
on 08/21/17
36.78 -3.97%
on 10/23/17
+2.37 (+7.19%)
since 08/17/17
52-Week
30.51 +15.77%
on 12/08/16
36.78 -3.97%
on 10/23/17
+3.59 (+11.31%)
since 11/17/16

Most Recent Stories

More News
Pfizer tells Nebraska not to use its drugs in execution

LINCOLN, Neb. (AP) — Pharmaceutical company Pfizer is demanding that Nebraska return any drugs manufactured by the company or an affiliate that the state plans to use in an execution.

PFE : 35.31 (-0.70%)
Cancer Space Update: Label Expansion for Three Major Drugs

This week three major drugs received approval for label expansion in new indications. Moreover, a small biotech launched its first drug as a treatment for kidney cancer.

AVEO : 3.13 (+2.29%)
CELG : 104.05 (+0.68%)
AZN : 33.47 (-0.15%)
BLUE : 161.85 (+1.06%)
MRK : 55.41 (+0.44%)
RHHBY : 29.0750 (+0.62%)
PFE : 35.31 (-0.70%)
Pfizer Receives FDA Approval for SUTENT(R) (sunitinib malate) as First and Only Adjuvant Treatment for Adult Patients at High Risk of Recurrent Renal Cell Carcinoma

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT(R) (sunitinib malate) to include the adjuvant treatment...

PFE : 35.31 (-0.70%)
AstraZeneca's Faslodex Gets FDA Nod for Use With Verzenio

AstraZeneca's (AZN) drug Faslodex received FDA approval for a new indication.

AZN : 33.47 (-0.15%)
JNJ : 138.28 (-0.42%)
LLY : 82.96 (-0.58%)
PFE : 35.31 (-0.70%)
IRX Therapeutics Appoints Luba Greenwood to Board of Directors

IRX Therapeutics, Inc. (IRX) today announced the appointment of Luba Greenwood, Vice President of Global Business Development and Mergers & Acquisitions at F. Hoffmann-La Roche, Diagnostics,...

PFE : 35.31 (-0.70%)
Novo Nordisk & 4 Other Pharma Stocks in Focus on World Diabetes Day

Despite pricing pressure & competition, the diabetes market remains lucrative given the prevalence of the disease and demand for better treatments. Novo Nordisk (NVO) is a key player in this market.

AZN : 33.47 (-0.15%)
NVO : 50.96 (+0.91%)
MRK : 55.41 (+0.44%)
LLY : 82.96 (-0.58%)
PFE : 35.31 (-0.70%)
SNY : 44.59 (-0.13%)
Merck (MRK) Gets CHMP Nod for Infection Candidate Prevymis

CHMP has given a positive opinion recommending the marketing approval of Merck's (MRK) Prevymis for the prevention of CMV infection.

LGND : 140.20 (-1.07%)
JNJ : 138.28 (-0.42%)
MRK : 55.41 (+0.44%)
PFE : 35.31 (-0.70%)
The Zacks Analyst Blog Highlights: Pfizer, Occidental Petroleum, Charles Schwab, Prudential and S&P Global

The Zacks Analyst Blog Highlights: Pfizer, Occidental Petroleum, Charles Schwab, Prudential and S&P Global

OXY : 68.28 (+1.65%)
PRU : 110.72 (+0.32%)
SPGI : 160.64 (+0.34%)
SCHW : 44.79 (+0.34%)
PFE : 35.31 (-0.70%)
Top Analyst Reports for Pfizer, Occidental Petroleum & Charles Schwab

Top Analyst Reports for Pfizer, Occidental Petroleum & Charles Schwab

OXY : 68.28 (+1.65%)
PRU : 110.72 (+0.32%)
SPGI : 160.64 (+0.34%)
SCHW : 44.79 (+0.34%)
BK : 52.64 (+0.78%)
PFE : 35.31 (-0.70%)
Arena (ARNA) Completes Enrolment in Etrasimod Phase II Study

Arena (ARNA) completed full enrollment with 157 patients in a phase II study evaluating etrasimod in ulcerative colitis (UC). Results from the study are expected in the first quarter of 2018.

LGND : 140.20 (-1.07%)
ARNA : 26.53 (-0.08%)
ABBV : 93.88 (-0.62%)
PFE : 35.31 (-0.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More

Business Summary

Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company's diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional...

See More

Key Turning Points

2nd Resistance Point 35.79
1st Resistance Point 35.68
Last Price 35.31
1st Support Level 35.35
2nd Support Level 35.13

See More

52-Week High 36.78
Last Price 35.31
Fibonacci 61.8% 34.38
Fibonacci 50% 33.65
Fibonacci 38.2% 32.91
52-Week Low 30.51

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart